ALSMA Stock Overview
S.M.A.I.O S.A. provides software, implantable devices, and associated services to treat spinal pathologies requiring surgery.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
S.M.A.I.O S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.18 |
| 52 Week High | €3.98 |
| 52 Week Low | €1.90 |
| Beta | 0.48 |
| 1 Month Change | 1.27% |
| 3 Month Change | 7.43% |
| 1 Year Change | -6.47% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -42.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALSMA | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | 1.3% | -0.08% | -0.2% |
| 1Y | -6.5% | 16.8% | 2.3% |
Return vs Industry: ALSMA underperformed the French Medical Equipment industry which returned 17.1% over the past year.
Return vs Market: ALSMA underperformed the French Market which returned 2.9% over the past year.
Price Volatility
| ALSMA volatility | |
|---|---|
| ALSMA Average Weekly Movement | 7.9% |
| Medical Equipment Industry Average Movement | 5.0% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.8% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALSMA has not had significant price volatility in the past 3 months.
Volatility Over Time: ALSMA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 38 | Philippe Roussouly | smaio.com |
S.M.A.I.O S.A. provides software, implantable devices, and associated services to treat spinal pathologies requiring surgery. The company was incorporated in 2009 and is based in Saint-Priest, France.
S.M.A.I.O S.A. Fundamentals Summary
| ALSMA fundamental statistics | |
|---|---|
| Market cap | €16.63m |
| Earnings (TTM) | -€902.77k |
| Revenue (TTM) | €6.91m |
2.4x
P/S Ratio-18.4x
P/E RatioIs ALSMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALSMA income statement (TTM) | |
|---|---|
| Revenue | €6.91m |
| Cost of Revenue | €3.05m |
| Gross Profit | €3.86m |
| Other Expenses | €4.76m |
| Earnings | -€902.77k |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Oct 15, 2024
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 55.85% |
| Net Profit Margin | -13.06% |
| Debt/Equity Ratio | 14.7% |
How did ALSMA perform over the long term?
See historical performance and comparison